Human T cells are lymphocytes that play a central role in the adaptive immune response to pathogens and diseased cells. They serve as critical starting materials across a broad range of research and therapeutic applications, including cell and gene therapy development, oncology, vaccine research, and immunotherapies such as CAR-T. T cells also mediate immune responses involved in organ transplant rejection, autoimmune diseases, and certain allergic reactions.
T cell subsets are defined by the expression of characteristic surface markers, including CD45, CD3, CD4, and CD8. These markers regulate functional activity and are widely used for phenotypic identification and confirmation of T cell populations.
Our human T cells are isolated from freshly collected leukopaks using immunomagnetic positive or negative selection methods. Purity and viability are verified through flow cytometry analysis. Leukopaks are obtained from healthy donors under informed consent through an Institutional Review Board (IRB)-approved protocol. Collections are performed at our donor center, which is FDA-registered, state-licensed, and accredited by both AABB and CLIA.
Peripheral blood mononuclear cells (PBMCs) are isolated onsite from freshly collected leukopaks using Ficoll density gradient centrifugation. Immediately following isolation, cells are cryopreserved in CryoStor® CS10 to maintain viability and functional integrity during storage and shipment.
Our standardized operating procedures are designed to ensure high yield, purity, and consistency of mononuclear cell preparations while minimizing contamination from granulocytes, erythrocytes, and platelets. Each PBMC preparation undergoes flow cytometry analysis to quantify white blood cell recovery, assess purity, and characterize the distribution of key immune cell subsets.
To further ensure product reliability, all PBMC lots are subjected to post-thaw quality control testing prior to release. These evaluations confirm cell recovery, viable cell counts, and overall viability, ensuring that researchers receive high-quality material suitable for immunology research, cell therapy development, and related applications.
Human natural killer (NK) cells are isolated from peripheral blood using immunomagnetic cell separation methods and can be enriched through either positive or negative selection strategies. These cells are characterized by surface expression of CD56 and play a key role in the innate immune response by recognizing and eliminating infected or malignant cells without prior antigen sensitization.
Because NK cells do not require activation by antigen-presenting cells, they can mount rapid cytotoxic responses against target cells. This property makes NK cells an attractive platform for immunotherapy development, and NK cell–based cancer therapies are currently under active evaluation in multiple clinical trials.
Chimeric antigen receptor (CAR) NK therapies are emerging as a promising alternative to CAR-T approaches. Studies suggest that CAR-NK therapies may offer an improved safety profile, with reduced risk of graft-versus-host disease (GvHD) and cytokine release syndrome. CAR-NK cells can mediate cytotoxicity through multiple mechanisms and have demonstrated improved infiltration into certain solid tumor environments.
Natural killer cells play a critical role in antibody-dependent cellular cytotoxicity (ADCC). Tumor-targeting monoclonal antibodies that recruit NK cell activity have shown therapeutic potential in malignancies such as neuroblastoma and melanoma. In addition, monoclonal antibodies can be used to enhance NK cell activation and cytotoxic function.
Adoptive transfer of NK cells is also being investigated in combination with other therapeutic strategies. Clinical studies are exploring NK cell infusion alongside CD34+ hematopoietic stem cells for the treatment of acute myeloid leukemia. Additional trials are evaluating the synergistic effects of NK cell therapies combined with monoclonal antibody treatments.
Monocytes are phagocytic immune cells that play a central role in innate immune responses. These circulating leukocytes contribute to pathogen clearance, inflammatory signaling, and tissue homeostasis. In addition to their direct antimicrobial activity, monocytes can mediate antibody-dependent cellular cytotoxicity and migrate rapidly to sites of infection or tissue damage in response to inflammatory cues. Under appropriate culture conditions, monocytes can differentiate into macrophages, dendritic cells, or Langerhans cells, making them valuable starting materials for immunology research and cell therapy development.
Monocytes represent approximately 10–30% of circulating white blood cells in peripheral blood and serve multiple immune functions, including vascular homeostasis and early immune surveillance during acute infection.
Our monocytes are isolated from peripheral blood mononuclear cells using advanced immunomagnetic cell separation methods. Both positive and negative selection strategies are available for the enrichment of CD14⁺ monocytes. Cell yield, purity, and viability are verified by flow cytometry analysis, with typical preparations achieving >90% purity and >95% viability.
Pan monocyte preparations include the full spectrum of monocyte subsets—classical, intermediate, and non-classical monocytes. These populations can be distinguished by differential expression of CD14 and CD16 surface markers. Negative selection methods remove non-target immune cells while preserving an untouched population of monocytes exhibiting variable CD14/CD16 expression profiles. CD14⁺ pan monocytes represent one of the most abundant circulating immune cell types and are widely used in immunological research and cell therapy applications.
Classical monocytes constitute approximately 80–85% of the total monocyte population. These cells are characterized by high CD14 expression and low CD16 expression (CD14++ CD16⁻/low). They primarily function as phagocytic cells involved in innate immune defense and exhibit strong migratory capacity to sites of inflammation.
Intermediate monocytes (CD14⁺ CD16⁺) account for roughly 5% of circulating monocytes. This subset displays features of both classical and non-classical monocytes and expresses elevated levels of antigen presentation–associated molecules.
Non-classical monocytes (CD14⁺ CD16++) comprise approximately 5–10% of the monocyte population. These cells are involved in immune surveillance and tissue repair processes and have been associated with vascular monitoring and wound healing functions.
Dendritic cells (DCs) are generated from purified monocytes and play a central role in antigen presentation and immune activation. CD14⁺ monocytes are first isolated by immunomagnetic positive selection and subsequently cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), which promotes differentiation into monocyte-derived dendritic cells. The presence of dendritic cells is confirmed through morphological evaluation and analysis of characteristic surface marker expression.
CD11c, a cell surface glycoprotein highly expressed on monocyte-derived immature dendritic cells, is commonly used as a marker to identify dendritic cells within white blood cell populations and to confirm post-selection purity. In peripheral blood, dendritic cells account for approximately 1% of circulating peripheral blood mononuclear cells (PBMCs). Due to their potent antigen-presenting capabilities, dendritic cells are widely used in in vitro immunological assays, including studies of T cell activation, antigen presentation, and contact sensitization.
Autologous dendritic cell vaccines are being investigated as a therapeutic strategy for cancer treatment. In these approaches, dendritic cells derived from a patient are engineered or loaded with tumor-associated antigens to stimulate targeted anti-tumor immune responses. Such therapies are currently being evaluated in clinical studies for diseases including leukemia.
Dendritic cell–based immunotherapies are also being explored as part of combination treatment strategies. Researchers are investigating their use alongside established modalities such as chemotherapy, monoclonal antibodies, and other immunotherapies to enhance and sustain anti-tumor immune responses.
Human B cells are key components of the adaptive immune system responsible for antigen recognition, antibody production, and the establishment of long-term immune memory. Through the diversity of the B cell receptor (BCR), B cells are capable of recognizing a wide range of antigens and contributing to immune surveillance and pathogen clearance. Mature B cells are typically characterized by the expression of surface markers such as CD19, CD20, and CD22.
Our human B cells are isolated from peripheral blood mononuclear cells using immunomagnetic cell separation techniques. Isolation can be performed through positive selection targeting CD20 or CD22 surface markers, or through negative selection strategies that remove non-target cell populations while preserving untouched B cells
In addition to their well-established role in antibody production and immune memory, B cells can function as antigen-presenting cells and participate in immune regulation. These properties make B cells promising candidates for cancer immunotherapy. Several clinical studies are currently investigating B cell–based cancer vaccines and CD40-activated B cells, which have demonstrated the ability to stimulate anti-tumor T cell responses.
B cells also play a significant role in the pathogenesis of many autoimmune diseases. As a result, targeted B cell depletion strategies are being actively explored as therapeutic approaches to treat autoimmune disorders. Clinical trials evaluating B cell depletion therapies aim to reduce pathogenic immune responses while preserving overall immune function.
Granulocytes are the most abundant class of white blood cells and play a critical role in the innate immune response. These cells originate from hematopoietic stem cells in the bone marrow and are characterized by cytoplasmic granules that contain enzymes and antimicrobial proteins used to combat infection and mediate inflammatory responses. Upon activation, granulocytes release these granule contents to destroy pathogens and contribute to immune signaling.
Granulocytes are typically classified into three major subtypes based on the composition of their granules: neutrophils, eosinophils, and basophils. Each subset performs specialized functions in host defense, including pathogen clearance, allergic response regulation, and inflammatory signaling.
Human granulocyte preparations are isolated using optimized separation protocols and characterized by flow cytometry. Final products are guaranteed to achieve >90% purity and >95% viability, as determined by flow cytometric analysis.
Conditions such as prolonged illness, intensive chemotherapy, or hematopoietic stem cell transplantation can lead to severe depletion of neutrophils and other granulocytic cells. In these cases, granulocyte transfusion therapy may be used to help restore innate immune function and reduce the risk of bacterial, viral, and fungal infections associated with neutropenia.
Emerging cellular immunotherapy approaches are exploring the infusion of immature immune cell populations capable of replenishing neutrophil levels in immunocompromised patients. Clinical trials are currently evaluating whether these therapies can reduce infection risk and improve recovery outcomes in patients undergoing treatments such as chemotherapy for leukemia.
Macrophages are phagocytic immune cells responsible for engulfing and eliminating pathogens, cellular debris, and foreign materials. They play a critical role in innate immunity by clearing damaged or dying cells, controlling microbial infections, and coordinating immune responses through cytokine signaling. Macrophages also contribute to immune surveillance and tissue homeostasis. Due to their functional versatility, macrophage-based cell therapies are being actively investigated for applications in cancer treatment, spinal cord injury, and autoimmune diseases.
Human macrophages are generated from purified CD14⁺ monocytes. Monocytes are isolated by immunomagnetic positive selection and subsequently cultured in the presence of specific differentiation factors to promote macrophage development. Macrophage identity and phenotype are confirmed through morphological assessment and analysis of characteristic biomarker expression.
Macrophages display significant functional plasticity and are broadly classified into two major activation states—M1 and M2—based on their biological functions and cytokine profiles.
M1 macrophages, also referred to as classically activated macrophages, are associated with pro-inflammatory immune responses. These cells produce inflammatory cytokines, exhibit strong antimicrobial activity, and contribute to host defense against pathogens.
M1 macrophages are derived from purified CD14⁺ monocytes that are positively selected using immunomagnetic separation and cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) for approximately 10 days. M1 phenotype is confirmed through morphological analysis and expression of characteristic biomarkers.
M2 macrophages, or alternatively activated macrophages, are primarily associated with tissue repair, immune regulation, and anti-inflammatory responses. They play roles in parasite defense, tissue remodeling, angiogenesis, and the resolution of inflammation.
M2 macrophages are generated from purified CD14⁺ monocytes using immunomagnetic positive selection followed by culture in the presence of macrophage colony-stimulating factor (M-CSF) for approximately 10 days. Phenotypic characterization is confirmed through morphological assessment and biomarker expression analyzed by flow cytometry.
Mixed macrophage populations are also derived from purified CD14⁺ monocytes using immunomagnetic selection methods. These cells are cultured in the presence of GM-CSF or M-CSF for approximately 10 days, resulting in heterogeneous macrophage populations that may include both M1- and M2-like cells, along with less common macrophage subtypes.
Actcell Labs Inc
1361 Amsterdam Ave.,
Floor 3, New York,
NY 10027, USA
+1 888 4880155
support@actcelllabs.com